These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23619367)

  • 1. Recent advances in niacin and lipid metabolism.
    Kamanna VS; Ganji SH; Kashyap ML
    Curr Opin Lipidol; 2013 Jun; 24(3):239-45. PubMed ID: 23619367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
    Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
    Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of niacin.
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2008 Apr; 101(8A):20B-26B. PubMed ID: 18375237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niacin and cholesterol: role in cardiovascular disease (review).
    Ganji SH; Kamanna VS; Kashyap ML
    J Nutr Biochem; 2003 Jun; 14(6):298-305. PubMed ID: 12873710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential.
    Gaidarov I; Chen X; Anthony T; Maciejewski-Lenoir D; Liaw C; Unett DJ
    Cell Signal; 2013 Oct; 25(10):2003-16. PubMed ID: 23770183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicotinic acid: recent developments.
    Kamanna VS; Vo A; Kashyap ML
    Curr Opin Cardiol; 2008 Jul; 23(4):393-8. PubMed ID: 18520725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Niacin: an old drug rejuvenated.
    Kamanna VS; Ganji SH; Kashyap ML
    Curr Atheroscler Rep; 2009 Jan; 11(1):45-51. PubMed ID: 19080727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes.
    Li X; Millar JS; Brownell N; Briand F; Rader DJ
    Biochem Pharmacol; 2010 Nov; 80(9):1450-7. PubMed ID: 20655299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.
    Lukasova M; Malaval C; Gille A; Kero J; Offermanns S
    J Clin Invest; 2011 Mar; 121(3):1163-73. PubMed ID: 21317532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.
    Lauring B; Taggart AK; Tata JR; Dunbar R; Caro L; Cheng K; Chin J; Colletti SL; Cote J; Khalilieh S; Liu J; Luo WL; Maclean AA; Peterson LB; Polis AB; Sirah W; Wu TJ; Liu X; Jin L; Wu K; Boatman PD; Semple G; Behan DP; Connolly DT; Lai E; Wagner JA; Wright SD; Cuffie C; Mitchel YB; Rader DJ; Paolini JF; Waters MG; Plump A
    Sci Transl Med; 2012 Aug; 4(148):148ra115. PubMed ID: 22914621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleiotropic effects of niacin: Current possibilities for its clinical use.
    Zeman M; Vecka M; Perlík F; Staňková B; Hromádka R; Tvrzická E; Širc J; Hrib J; Žák A
    Acta Pharm; 2016 Dec; 66(4):449-469. PubMed ID: 27749252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention.
    Parhofer KG
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):414-7. PubMed ID: 16151973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia.
    Hu M; Yang YL; Ng CF; Lee CP; Lee VWY; Hanada H; Masuda D; Yamashita S; Tomlinson B
    Medicine (Baltimore); 2015 May; 94(20):e881. PubMed ID: 25997070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapies to increase apolipoprotein AI and HDL for the treatment of atherosclerosis.
    Wong NC
    Curr Opin Investig Drugs; 2007 Sep; 8(9):718-28. PubMed ID: 17729183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid.
    Pike NB
    J Clin Invest; 2005 Dec; 115(12):3400-3. PubMed ID: 16322787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.
    Benyó Z; Gille A; Kero J; Csiky M; Suchánková MC; Nüsing RM; Moers A; Pfeffer K; Offermanns S
    J Clin Invest; 2005 Dec; 115(12):3634-40. PubMed ID: 16322797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niacin therapy in atherosclerosis.
    Meyers CD; Kamanna VS; Kashyap ML
    Curr Opin Lipidol; 2004 Dec; 15(6):659-65. PubMed ID: 15529025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
    van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
    Vosper H
    Br J Pharmacol; 2009 Sep; 158(2):429-41. PubMed ID: 19627285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.